CNO-PA Q4 2025 Earnings Call Summary

CNO Financial Group Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Operating Earnings Per Share: Increased 11% to $4.40 for Q4 2025; full year operating earnings per diluted share was $4.02, exceeding guidance.
Operating Return on Equity (ROE): Improved to 11.4%, up from 10% in 2024, with a target of 12% by 2027.
Total New Annualized Premium (NAP): Grew 15% year-over-year, marking the 14th consecutive quarter of sales growth.
Book Value Per Diluted Share: Reached $38.81, representing a 7% compound annual growth rate over the past three years.
Shareholder Returns: $386 million returned to shareholders, including an 11% increase in dividends.

2. Strategic Updates and Business Highlights

Consumer Division: Achieved record total NAP, with significant growth in life, supplemental health, and Medicare Supplement products. Direct-to-consumer life sales surged 20%.
Worksite Division: Experienced record insurance sales, up 15% for the year, with notable growth in life and hospital indemnity insurance.
Agent Growth: Continued growth in producing agent count for the 12th consecutive quarter, emphasizing agent productivity as a priority.
Technology Investment: A three-year initiative to invest $170 million in tech modernization is on track, with $20 million deployed in 2025 and $75 million expected in 2026.

3. Forward Guidance and Outlook

2026 Guidance: Operating earnings per share projected between $4.25 and $4.45, reflecting an 8% increase at the midpoint from 2025. Expense ratio expected to range from 18.8% to 19.2%.
Free Cash Flow: Anticipated between $200 million and $250 million, supporting capital deployment and business investments.
Market Conditions: Outlook assumes a stable macro environment, with ongoing monitoring of economic conditions impacting consumer behavior.

4. Bad News, Challenges, or Points of Concern

Economic Headwinds: Potential challenges due to rising layoffs and economic uncertainty could impact discretionary purchases, particularly in annuities and life insurance.
Medicare Advantage Market: Anticipated decline in Medicare Advantage sales due to market pressures, with a shift towards Medicare Supplement products expected to continue.
Visibility Issues: Management expressed concerns about the lack of visibility in predicting market conditions, indicating a cautious approach moving forward.

5. Notable Q&A Insights

Agent Count Growth: Management confirmed expectations for continued growth in producing agent count, emphasizing productivity as a primary focus.
Investment Strategy: Discussion on maintaining portfolio quality while exploring higher-yielding assets, with a cautious approach to risk management.
Medicare Dynamics: Insights on the impact of Medicare Supplement versus Medicare Advantage on financials, with a preference for the former due to better control over the product lifecycle and customer demographics.
Regulatory Relationships: Management highlighted strong relationships with regulators, emphasizing a respectful approach to regulatory processes regarding future transactions.

Overall, CNO Financial Group reported strong financial results for Q4 2025, driven by consistent sales growth and strategic initiatives, while also navigating potential economic challenges and market dynamics.

CNO-PA — CNO Financial Group, Inc. 5.125